Search academic texts

Information × Registration Number 0225U001135, (0122U000419) , R & D reports Title "Investigate the phenotypic hormonal and metabolic features of the use of incretinomimetics and inhibitors of sodium-dependent co-transporter of type 2 glucose in patients with type 2 diabetes mellitus in the postcoptic period" popup.stage_title Дослідити фенотипові гормонально-метаболічні особливості застосування інкретиноміметиків та інгібіторів натрій залежного ко-транспортеру глюкози-2 у хворих на цукровий діабет 2 типу у постковідному періоді Head Zinych Olesia V., Доктор медичних наукKorpachev Vadym V., Доктор медичних наук Registration Date 26-01-2025 Organization State Institute "V.P. Komissarenko Institute Of Endocrinology And Metabolism of The National Academy of Medical Science of Ukraine" popup.description1 To investigate features of incretin mimetics and sodium-glucose co-transporter 2 inhibitors usage depending on different hormonal and metabolic phenotypes in patients with type 2 diabetes and post-COVID period popup.description2 It was established that in patients with the MTHFR 677 C/T gene polymorphism (C/C and C/T), an increase in homocysteine levels was observed during the acute phase of COVID-19, which normalized after 9 months in both groups, alongside an increase in folic acid levels in the MTHFR 677 subgroup with the C/T allele. The serotonin level in type 2 diabetes (T2D) in the SGLT2 inhibitor treatment group increased after recovery in both MTHFR 677 C/T subgroups (C/C and C/T) compared to baseline levels during the acute phase of COVID-19. In both MTHFR 677 C/T subgroups, a moderate negative correlation between homocysteine and serotonin levels was observed following SGLT2 inhibitor treatment. It was found that T2D patients, during the acute phase of COVID-19 and 9 months after recovery, had higher levels of the cardiovascular pathology biomarker ST2 than individuals without T2D. However, the administration of SGLT2 inhibitors contributed to a reduction in ST2 levels compared to traditional glucose-lowering therapy, indicating a decreased risk of heart failure. After 12 months of treatment with the SGLT2 inhibitor, there was a decrease in the cortisol/DHEA-S ratio, a marker of stress resilience, due to an increase in DHEA-S concentration. It was also found that the additional use of GLP-1 receptor agonists (GLP-1 RAs) alongside basic glucose-lowering therapy significantly increased the level of osteocalcin in the blood, demonstrating a positive effect on the cardiovascular system, in contrast to the neutral effect of SGLT2 inhibitors on osteocalcin. The administration of GLP-1 RAs for 6 months improved body composition, carbohydrate metabolism, and lipid profiles, as well as increased the concentrations of short-chain fatty acids in stool filtrates. This may promote the synthesis of endogenous incretins, restore impaired metabolic activity of the gut microbiota, and minimize the risk of development and progression of cardiovascular diseases in T2D patients. Product Description popup.authors Zinych Olesia V. Kovalchuk Alla V. Kushnarova Nataliia M. Prybyla Olha V. Khovaka Vitalii V. Shyshkan-Shyshova Kateryna O. popup.nrat_date 2025-01-26 Close